Article | Published:

Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result

Abstract

Purpose

This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions.

Methods

Participants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure.

Results

Eighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5% noncarriers) intended to seek confirmatory testing within six months and 20% (2.5% noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028).

Conclusion

Recipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Jarvik GP, Amendola LM, Berg JS, et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet. 2014;94:818–826.

  2. 2.

    Bollinger J, Scott J, Dvoskin R, Kaufman D. Public preferences regarding the return of individual genetic research results: findings from a qualitative focus group study. Genet Med. 2012;14:451–457.

  3. 3.

    Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendations. J Law Med Ethics. 2008;36:219–248.

  4. 4.

    Fabsitz RR, McGuire A, Sharp RR, et al. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet. 2010;3:574–580.

  5. 5.

    Beskow LM, Burke W. Offering individual genetic research results: context matters. Sci Transl Med. 2010;2:38cm20.

  6. 6.

    Burke W, Evans BJ, Jarvik GP. Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet. 2014;0:105–111.

  7. 7.

    Evans BJ. Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:915–920.

  8. 8.

    Wong CA, Hernandez AF, Califf RM. Return of research results to study participants: uncharted and untested. JAMA. 2018;320:435–436.

  9. 9.

    McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011;19:472–478.

  10. 10.

    Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401–2409.

  11. 11.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

  12. 12.

    Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51:14–24.

  13. 13.

    Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43:548–553.

  14. 14.

    National Cancer Institute. Cancer stat facts: melanoma of the skin. 2017. National Cancer Institute. https://seer.cancer.gov/statfacts/html/melan.html. Accessed April 16, 2018.

  15. 15.

    Eckerle Mize D, Bishop M, Resse E, Sluzevich J. Familial atypical multiple mole melanoma syndrome. In: Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M, eds. Cancer Syndromes. Bethesda, MD: National Center for Biotechnology Information; 2009: https://www.ncbi.nlm.nih.gov/books/NBK7030/. Accessed April 10, 2019.

  16. 16.

    Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–347.

  17. 17.

    Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–262.

  18. 18.

    Curiel-Lewandrowski C, Chen SC, Swetter SM, Melanoma Prevention Working Group-Pigmented Skin Lesion Subcommittee. Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep. 2012;14:458–467.

  19. 19.

    Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol. 2014;20:10778–10789.

  20. 20.

    Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev. 2013;22:1687–1697.

  21. 21.

    Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med. 2009;11:265–278.

  22. 22.

    Christensen KD, Roberts JS, Shalowitz DI, et al. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev. 2011;20:522–529.

  23. 23.

    Glanz K, Volpicelli K, Kanetsky PA, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 2013;22:607–614.

  24. 24.

    Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2006;15:704–710.

  25. 25.

    Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–D1067.

  26. 26.

    ClinVar. NM_000077.4(CDKN2A):c.47T>G (p.Leu16Arg). ClinVar. 2018; https://www.ncbi.nlm.nih.gov/clinvar/variation/219815/. Accessed 21 October 2018.

  27. 27.

    Marks D, Horn IP, Hogenson TL, et al. Reducing protein stability underlies the protumoral function of L16R(47T>G) CDKN2A, a mutation associated with familial pancreatic cancer. Paper presented at: American Assocaition for Cancer Research (AACR) Special Conference: Pancreatic Cancer: Advances in Science and Clinical Care; September, 2018; Boston, MA.

  28. 28.

    Rimer BK, Glanz K. Theory at a Glance: A Guide for Health Promotion Practice (Second Edition). Washington D.C.: U.S. Department of Health and Human Services; 2005. https://cancercontrol.cancer.gov/brp/research/theories_project/theory.pdf. Accessed April 10, 2019.

  29. 29.

    Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology. 2018;155:740–.e742.

  30. 30.

    Vasen H, Ibrahim I, Ponce CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 2016;34:2010–2019.

  31. 31.

    Graves KD, Sinicrope PS, Esplen MJ, et al. Communication of genetic test results to family and health care providers following disclosure of research results. Genet Med. 2014;16:294–301.

  32. 32.

    Bradbury AR, Patrick-Miller L, Egleston BL, et al. Returning individual genetic research results to research participants: uptake and outcomes among patients with breast cancer. JCO Precision Oncol. 2018;2:1–24.

  33. 33.

    O’Daniel J, Haga SB. Public perspectives on returning genetics and genomics research results. Public Health Genomics. 2011;14:346–355.

  34. 34.

    Meulenkamp TM, Gevers SK, Bovenberg JA, Koppelman GH, van Hylckama Vlieg A, Smets EM. Communication of biobanks’ research results: what do (potential) participants want? Am J Med Genet A. 2010;152A:2482–2492.

  35. 35.

    Schwartz MD, Valdimarsdottir HB, Peshkin BN, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol. 2014;32:618–626.

  36. 36.

    Jenkins J, Calzone KA, Dimond E, et al. Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genet Med. 2007;9:487–495.

  37. 37.

    DeMarco TA, Peshkin BN, Mars BD, Tercyak KP. Patient satisfaction with cancer genetic counseling: a psychometric analysis of the Genetic Counseling Satisfaction Scale. J Genet Couns. 2004;13:293–304.

  38. 38.

    Hays RD, Hayashi T, Stewart AL. A five-item measure of socially desirable response set. Educ Psychol Meas. 1989;49:629–636.

  39. 39.

    Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: A meta‐analysis of effects and processes. In: Zanna M, ed. Advances in Experimental Social Psychology. San Diego, CA: Academic Press; 2006:69–119.

  40. 40.

    Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol. 2009;64:527–537.

Download references

Acknowledgements

This research was supported in part by National Institutes of Health (NIH) grants R01 CA97075 and R01 CA208517 and the Rolfe Foundation for Pancreatic Cancer. We gratefully acknowledge the clinical expertise of Noralane Lindor, Robert R. McWilliams, and Katrina Pedersen; the study coordination efforts of Bridget Rathbun; and the data management support of Que Luu, Megan Reichmann, Ryan Wuertz, and Sarah Amundson.

Author information

Disclosure

The authors declare no conflicts of interest.

Correspondence to Carmen Radecki Breitkopf PhD.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • genetic research result
  • pancreatic cancer
  • melanoma
  • risk perception
  • cancer screening
Fig. 1